Compare 8x8 Inc (EGHT) vs BIO-TECHNE Corp (TECH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
8x8 Inc vs BIO-TECHNE Corp — how do they compare? 8x8 Inc trades at $2.05 (market cap $279.31M), while BIO-TECHNE Corp trades at $71.78 (market cap $11.14B). The key difference: BIO-TECHNE Corp is far larger — about 39.9× 8x8 Inc's market cap, and BIO-TECHNE Corp pays a 0.45% dividend while 8x8 Inc pays none. Which is the better fit depends on your goals.
| EGHT | TECH | |
|---|---|---|
Market Cap | $279.31M | $11.14B |
Sector | Technology | Health |
52-Week High | $2.76 | $71.48 |
52-Week Low | $1.59 | $43.31 |
Enterprise Value | $556.99M | $11.22B |
Dividend Yield | — | 0.45% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EGHT (8x8, Inc.) trades at $2.035, down 6.22% on the day. The stock shows a bullish technical signal from moving averages, though oscillators are neutral. Fundamentally, the company reported a net loss of $27.21M for 2025 but has beaten EPS estimates for three consecutive quarters. Recent news highlights product innovation with AI Routing and Pulse solutions, and the company was named a 2026 MetriStar Top Provider for CPaaS. Revenue grew to $715.07M in 2025, with a forecasted return to profitability in 2026.
The outlook hinges on the company's transition to profitability, projected for 2026 with a net profit of $2M. Investment opportunities include continued revenue growth, successful execution of new AI-driven products, and cost discipline. Key risks are the high P/E ratio of 197, significant long-term debt of $338.37M, and the challenge of sustaining recent earnings beats. Analyst sentiment is mixed but leans positive, with 39% Buy ratings.
Bio-Techne (TECH) trades at $71.69, up 0.65% today, near the $73.00 acquisition offer from Merck KGaA announced June 25, 2026. The stock shows bullish technical signals with moving averages supporting upside, though RSI indicates potential overbought conditions. Fundamentally, revenue held at $1.22B in 2025, but net income fell to $73.40M with margin compression. Analysts are split 50/50 buy/hold with a $67.75 consensus target, below the current price, reflecting acquisition uncertainty.
The outlook hinges on the Merck deal closure at $73.00, offering a 1.8% premium from current levels. Risks include shareholder litigation challenging the transaction's fairness and regulatory approval delays. Without the deal, high P/E of 102.12 and declining profitability pose downside risks. The acquisition provides a near-term floor, but execution volatility remains a concern for long-term investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About 8x8 Inc
8x8 is a provider of integrated cloud communications and contact center solutions. Its platform combines voice, video, chat, and contact center functionality into a single application to help businesses collaborate.
Read more on EGHT →About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →
